Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.68 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27543803 | 0.92 | BCL9 (0.57) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5524169 | 0.91 | F2 (0.58) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL7069631 | 0.90 | BCL9 (0.56) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4608246 | 0.89 | BCL9 (0.55) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL9168629 | 0.89 | BCL9 (0.55) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL29769253 | 0.89 | BCL9 (0.55) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL9551670 | 0.88 | F2 (0.56) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5153071 | 0.88 | ACHE (0.59) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL27606934 | 0.86 | BCL9 (0.54) | BCL9CTNNB1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5524165 | 0.85 | F2 (0.53) | BCL9CTNNB1KMT2AMAPTF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354931-B2 | Treating obstructive airway disorders using nontoxic drug | ROCHE PALO ALTO LLC (US) | 2008-04-08 | — | — | US | disclosed |
| CN-101027283-A | 3,4-disubstituted maleimides for use as vascular damaging agents | ASTRAZENECA AB (SE) | 2007-08-29 | — | — | CN | disclosed |
| EP-1442032-B1 | HETEROCYCLIC RETINOID COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| CN-1283635-C | Heterocyclic retinoid compounds | HOFFMANN LA ROCHE (CH) | 2006-11-08 | — | — | CN | disclosed |
| CN-1809561-A | Phenylacetamides and their use as glucokinase modulators | PROSIDION LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| US-20050049238-A1 | Heterocyclic retinoid compounds | KLAUS MICHAEL (DE) | 2005-03-03 | — | — | US | disclosed |
| CN-1578776-A | Heterocyclic retinoid compounds | HOFFMANN LA ROCHE (CH) | 2005-02-09 | — | — | CN | disclosed |
| US-6818652-B2 | THERAPEUTIC TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CANCER AND DERMATOLOGICAL SKIN DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-16 | — | — | US | disclosed |
| EP-1442032-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| CN-1150195-C | Bicyclic nitrogen heterocycles | - | 2004-05-19 | — | — | CN | disclosed |
| US-20030158178-A1 | Heterocyclic retinoid compounds | SYNTEX (U.S.A.) LLC | 2003-08-21 | — | — | US | disclosed |
| WO-2003037882-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| CN-1324360-A | Bicyclic nitrogen heterocycles | HOFFMANN LA ROCHE (CH) | 2001-11-28 | — | — | CN | disclosed |
| CN-1043766-C | Indole derivative and preparation and pharmaceutical using of same | TORAY INDUSTRIES (JP) | 1999-06-23 | — | — | CN | disclosed |
| CN-1092425-A | Indole derivatives, its manufacture method and medicinal use thereof | TORAY INDUSTRIES (JP) | 1994-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049238-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | BCL9 1683/4885CTNNB1 2358/4885KMT2A 3662/4885 |
| US-20030158178-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | BCL9 1683/4885CTNNB1 2358/4885KMT2A 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.